Pilot Study of Bevacizumab (Avastin) in Patients With Septic Shock

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Beth Israel Deaconess Medical Center
Study ID
NCT01063010
Status
Withdrawn

Conditions

  • Septic Shock

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    Administered intravenously 10 mg/kg over 90 minutes (+ 15 minutes)
  • Placebo — DRUG
    Placebo administered intravenously for 90 minutes (+ 15 minutes)

Study Details

The purpose of this study is to perform a pilot study to assess the potential use of Bevacizumab (a vascular endothelial growth factor (VEGF) inhibitor) in sepsis.

Key Dates

First listed
Feb 5, 2010
Start date
Feb 28, 2010
Status verified
Oct 2024
Primary completion
Jan 31, 2015
Completion
Jan 31, 2015

Study Design

Enrollment
0 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Placebo Comparator: Placebo
    Placebo IV for 90 minutes (+ 15 minutes)
  • Experimental: Bevicizumab
    IV infusion over 90 minutes

Primary Outcome Measure

The change in Sequential Organ Failure Assessment score (SOFA) to assess reduction in organ failure [ Time Frame: Between 0 and 72 hours ]

Locations (3)

FacilityCityStateZIPSite coordinators
Beth Israel Medical CenterBostonMassachusetts02215-
Cooper University HospitalCamdenNew Jersey08103-
Carolinas Medical CenterCharlotteNorth Carolina28203-

Find similar trials in Boston, MA

By research site
Beth Israel Medical Center· Boston, MACooper University Hospital· Camden, NJCarolinas Medical Center· Charlotte, NC

Related Studies